Regeneration

• Paris hosting the Olympic and Paralympic Games this summer provides France with a huge geopolitical opportunity.
• Former French president François Hollande was credited with instigating the successful bid to stage the 2024 Games, 100 years after Paris was last host in 1924.
• But it is Emmanuel Macron who has enjoyed taking up the mantle in his quest to present a new vision of France.
• Some believe Macron being president was just what the Games needed, given his apparent quest to transform France into a more outward-looking, progressive nation.
• Indeed, Macron has proved adept at playing soft power games through sport (including his efforts to keep the footballer Kylian Mbappé playing in France).

City of light (and dark)

• Elsewhere, in a city that struggles to cope with traffic density, transport arrangements and problems with accommodation are worrying some officials as the Olympics approaches.
• By the end of September, it could be that many people across the world have a much more positive view of France and its capital city.
• Problems are mounting that could well undermine one of the president’s cornerstone projects in projecting his vision of a new France.

The authors do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

• Under the terms of the LOI, Sustainable Green Team, Ltd .
• will grant its exclusive right to manufacture, distribute, and sell its flagship products, HUMISOIL® , XLR8®Bio , and other mutually agreed-upon products in the designated territories.
• At the same time, the Partner will pay SGTM a revenue share or licensing fee for any products the Partner manufactures.
• The Caribbean Partner's expertise and local presence in the designated territories will play a significant role in driving the success of this agreement."

• “We are very excited to announce the initial response data from the first two type 1 diabetes patients enrolled in the COVALENT-112 study.
• Both patients showed improvement in measures of beta-cell function after only 4 weeks of dosing with BMF-219.
• The trial includes an open label portion for adults with type 1 diabetes up to 15 years since diagnosis.
• It has been exciting to participate in this study and explore this new pathway for the benefit of our patients.

• SZN-043 demonstrated acceptable safety and tolerability in all subjects, with evidence of target engagement, Wnt signal activation and effects on liver function.
• The observed safety and pharmacodynamic activity were the basis for the Company’s previous announcement that it planned to initiate enrollment in the Phase 1b study in alcohol-associated hepatitis.
• The randomized, placebo-controlled Phase 1a trial enrolled a total of 48 subjects, including 40 healthy volunteers and 8 patients with cirrhosis and a history of liver disease.
• Cirrhotic patients also showed evidence of liver function effects after treatment with SZN-043 as measured by HepQuant which is a test that measures cholate clearance, a liver specific function that quantifies liver function.